ECTS2016 Oral Communications Clinical trials and osteoporosis treatment (6 abstracts)
Secular trends in prescription incidence of different anti-osteoporotic drugs in the UK population aged 50 years or above from 1990 till 2012
Robert van der Velde 1, , Caroline Wyers 1, , Piet Geusens 3, , Joop van den Bergh 1, , Frank de Vries 5 , Cyrus Cooper 6, , Tjeerd-Pieter vandeStaa 9 & Nicholas Harvey 6,
1Department of Internal Medicine, VieCuri Medical Centre, Venlo, The Netherlands; 2Department of Internal Medicine, NUTRIM School of Nutrition & Translational Research in Metabolism, Maastricht University Medical Centre+, Maastricht, The Netherlands; 3Department of Internal Medicine, Subdivision Rheumatology, CAPHRI, Maastricht University Medical Centre+, Maastricht, The Netherlands; 4Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium; 5Department of Clinical Pharmacology and Toxicology, University Medical Centre Maastricht, Maastricht, The Netherlands; 6MRC Lifecourse Epidemiology Unit, Southampton General Hospital, University of Southampton, Southampton, UK; 7NIHR Musculoskeletal Biomedical Research Unit, Institute of Musculoskeletal Sciences, University of Oxford, Oxford, UK; 8NIHR Southampton Nutrition Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK; 9Health eResearch Centre, University of Manchester, Manchester, UK.
Objective: To study the trends in prescription of different anti-osteoporotic drugs (AOD) in the UK population aged 50 years or above from 1990 till 2012.
Methods: Retrospective observational study using the CPRD data link representative for the total UK population. The incidence of prescription of a specific AOD was calculated by dividing the number of prescriptions by the total person-years (py) of follow-up.
Results: AOD prescription increased in women from 1990 till 2006 (from 2.3/10,000 py to 169.7/10,000 py), followed by a plateau of two years and subsequently a 12% decrease in the last four years, in spite of the introduction of ibandronate and strontium ranelate in 2005–2006. In men a steep increase from 1990 to 2007 (from 1.4/10,000 py to 45/10,000 py) was followed by a plateau. AOD prescriptions were mostly bisphosphonates (>90%). Until 2000 etidronate was the dominant bisphosphonate, after 2000 this was alendronate. Prescriptions for AOD increased with age, with the biggest increment in women, up to the age group of 85–89 in which the incidence was 248.9/10,000 py in women and 119.3/10,000 py in men. There were significant regional differences in the prescriptions for AOD with the highest incidence in women and men in Northern Ireland and the lowest in East Midlands (women), Yorkshire and the Humber region (men). The prescription of AOD also differed markedly between ethnic groups with the highest differences seen in women, were the incidence in black women is only half that in white and Asian women.
Conclusion: Overall AOD prescription incidence across the UK showed a dramatic increase from 1990 to 2009 in women, followed by a decrease from 2009 to 2012, while in men the increase stabilized. Almost all AOD prescriptions were bisphosphonates. Prescriptions incidences were substantially higher in women and increased with age. There were marked regional and ethnical differences.
Article tools
My recent searches
My recently viewed abstracts
Authors
Bone Abstracts
ISSN 2052-1219 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more